Starsource Multitrade Ltd
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]
- Market Cap ₹ 15.8 Cr.
- Current Price ₹ 105
- High / Low ₹ 153 / 70.0
- Stock P/E 143
- Book Value ₹ 24.5
- Dividend Yield 0.00 %
- ROCE %
- ROE 3.00 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 4.29 times its book value
- Promoter holding is low: 27.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | |
|---|---|
| 0.00 | |
| 1.84 | |
| Operating Profit | -1.84 |
| OPM % | |
| 0.49 | |
| Interest | 0.00 |
| Depreciation | 0.00 |
| Profit before tax | -1.35 |
| Tax % | 7.41% |
| -1.45 | |
| EPS in Rs | -9.67 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 33% |
| 3 Years: | 48% |
| 1 Year: | -10% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | |
|---|---|
| Equity Capital | 1.50 |
| Reserves | 2.17 |
| 0.00 | |
| 0.20 | |
| Total Liabilities | 3.87 |
| 0.00 | |
| CWIP | 0.00 |
| Investments | 0.02 |
| 3.85 | |
| Total Assets | 3.87 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | |
|---|---|
| -2.09 | |
| 2.15 | |
| 0.00 | |
| Net Cash Flow | 0.06 |
| Free Cash Flow | -2.09 |
| CFO/OP | 109% |
Ratios
Consolidated / View Standalone
| Mar 2016 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Inter-Corporate Deposit (ICD) Outstanding INR Thousands ・Standalone data |
|
||||||||||
| Investment in Mutual Funds INR Thousands ・Standalone data |
|||||||||||
| Number of Equity Investee Companies count ・Standalone data |
|||||||||||
| Number of Mutual Fund Schemes Held count ・Standalone data |
|||||||||||
| Bank Term Deposits (HDFC FD and Other Bank Balances) INR Thousands ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Complinace Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended on Sep. 30, 2026.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 84th AGM voting results show resolutions 1 and 2 passed on September 28, 2026.
- Shareholder Meeting / Postal Ballot-Outcome of AGM
- Closure of Trading Window
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication - Post dispatch of Annual General Meeting to be held on September 28, 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Transition:
The earlier pharmaceutical and bulk-drug business had been disposed of, leaving the company largely dependent on interest, dividend, and investment income for several years. After a 2025 change in control, its objects were changed to include commodity trading, and the company was renamed Starsource Multitrade Ltd w.e.f. 01.10.2025. [1]